

Final Report
Sensitive early indicators of hepatic and kidney damage in workers exposed to Jet Fuel
Risk Assessment of Acute Exposure to Jet Fuel

Introduction:

Sensitive assays for liver and kidney damage provide an opportunity to evaluate early hepatic and renal damage in workers exposed to JP8 jet fuel. In this study, an assay for the cytoplasmic enzyme, plasma alpha-glutathione S-transferase (alpha-GST), tested the association between JP8 exposure and hepatic damage. Over 85% of alpha-GST in humans is found in hepatocytes and is released into the blood upon hepatic damage. As a result of its short half-life, plasma alpha-GST rises rapidly when hepatocytes are damaged and returns rapidly to baseline when damage is repaired. Plasma alpha-GST is a more sensitive indicator of damage than alanine aminotransferase and aspartate aminotransferase (Clarke et al, 1997; Rees et al, 1995). In an earlier study, JP8 workers had no significant changes in liver function measured by alanine aminotransferase and aspartate aminotransferase. However, some have questioned the use of these measurements for assessing hepatocyte damage since levels may be normal in some people with chronic liver disease (Clarke et al, 1997).

Two additional tests which measure urinary alpha or pi glutathione S-transferase (GST) are more sensitive for detection of early kidney damage than serum creatinine and blood urea nitrogen assays. The latter assays require a considerable loss of renal capacity before test values are significantly elevated. In earlier work, there were no significant differences in kidney function measured by BUN and creatinine in JP8 exposed and unexposed workers (Gould, 1998). In the kidney, alpha-GST is located only in the epithelial cells in the proximal tubule; pi-GST is localized within the epithelial cells in the distal tubules (Sundberg et al, 1994). Monitoring the urinary levels of these enzymes has proven valuable in monitoring kidney transplant patients to differentiate between transplant rejection and nephrotoxicity without the necessity of a biopsy (Sundberg et al, 1994).

For this research, enzyme-immunoassays were used to measure hep alpha-GST in subject plasma to monitor early signs of hepatic damage; neph alpha- and pi-GST in urine were used for the detection of early kidney tubule damage.

Methods:

Study population: Exposed workers were tank-entry personnel with at least nine months of persistent exposure to jet fuel, i.e., one-hour entry, twice a week, validated against shop records. The unexposed group consisted of US Air Force personnel who do not routinely work with or have significant exposure to fuels or solvents. Participants were chosen from among those meeting eligible criteria from six USAF bases: Davis Monthan AFB, AZ, Seymour Johnson AFB, NC, Langley AFB, VA, Pope AFB, NC, Little Rock AFB, AR, and Hurlbert Field, FL. Exclusion criteria are history of autoimmune disease, cancer, diabetes, and immune altering medication. Participants received \$50 for their time and inconvenience.

Participants completed a questionnaire to provide job, exposure, medical, and demographic information.

Sample Collection: Venous blood samples were collected from 107 individuals using 10 ml EDTA tubes. Pre- and post-shift samples were collected for all subjects. Blood samples were shipped on ice to the NIOSH laboratory by next day courier. At the NIOSH laboratories, samples were spun in a centrifuge to separate plasma from packed cells and plasma was transferred to screw-top polypropylene cryovials (Cat no. 60-542, Sarstedt, Inc.) approximately 24 hours after blood collection, and kept frozen at -80°C until assayed. Pre- and post-shift urine samples were collected from subjects and shipped on ice to the NIOSH laboratory by next day courier. At the NIOSH laboratories samples were divided into aliquots for respective studies. Samples destined for determination of neph alpha- and pi-GST were prepared for storage by the addition of stabilizing buffer (Biotrin International, 20% urine volume) and samples were frozen at -80°C until thawed for assay.

All samples were randomly numbered for blinded analysis. Plasma samples were thawed and assayed in duplicate for Hep alpha GST using commercial immunoassay kits (Biotrin International, Cat # BIO60HEPA). Urine samples were thawed and assayed for both neph alpha- and pi-GST using commercial immunoassay kits (Biotrin International, BIO66NEPHA and BIO69NEPHPI, respectively).

Statistical Analyses:

Pearson correlation coefficients were derived for each of the enzyme variables as well as pre- and post-shift change against the following variables:

Age, Base, Mthjob, Hisp, Pexert, Mental, Natlogpass, Natlogpre_n, Natlogpost_n, height, weight, BMI, Smoker, Alcohol, Alcdown, Alcabout, Alcuse, Alcsitng, Physwrk, Physntwk, Analyco24, and Noalcdurstudy.

Univariate analyses of variance were conducted for each enzyme variable against the following variables:

Race, Hisp, Category, Smoker, Alcohol, Analyco24, and Noalcdurstudy.

Status:

Analysis for hep alpha-GST for plasma and neph alpha- and pi-GST in urine samples from all subjects have been completed and statistical analysis conducted as described above.

Findings:

Assessment of liver toxicity: Levels of serum hep alpha-GST in the study subjects were well within the normal range for this measure; no differences were observed indicative of hepatic changes attributable to any of the variables examined (Table 1).

Assessment of kidney toxicity: Levels of urinary neph alpha- and pi-GST in the study subjects fell within the normal range for healthy subjects; no differences were observed indicative of renal changes attributable to any of the variables examined (Table2) .

Assessment of urine creatinine: Creatinine was used to normalize neph alpha- and pi-GST to correct for urinary dilution. One finding of this study was that individuals from exposure category 3 had significantly higher levels of urinary creatinine in their post shift samples. While the mean values are within normal ranges (0.25-4.0 mg/ml) for this measure in healthy

individuals and are not indicative of clinical disease, they are evidence of more concentrated urine (Table 3).

Discussion/Conclusions:

The study group represents a very healthy segment of the population. Sensitive measures for liver and kidney damage did not detect any adverse effects in specimens from this study group. Evidence of elevated creatinine in the mean post-shift samples of exposure category 3 was seen. However, while these values are within normal clinical ranges, they are consistent with concentrated urine indicative of mild dehydration. Because of the elevated urine creatinine levels in post-shift samples of exposure category 3, there is an apparent decrease in pre- vs. post-shift levels of Neph alpha- and pi-GST in these samples. This is an artifact of the concentrated creatinine. When levels of urinary GSTs are expressed on a per volume basis, levels remain unchanged between pre- and post-shift samples.

References

- Clarke H, Egan DA, Hefferman M, Doyle S, Byrne C, Kilty C, Ryan MP. Alpha glutathione S-transferase release, an early indicator of hepatotoxicity in the rat. *Human Exp Toxicol*. 16: 154-157, 1997.
- Gould, WD. Occupational Assessment of Air Force Personnel Exposure to Jet Fuel before and after Conversion to JP8. International Conference on the Environmental Health and Safety of Jet Fuel. April 2, 1998.
- Rees GW, Trull AK, Doyle S. Evaluation of an enzyme-immunometric assay for serum alpha glutathione S-transferase. *Ann Clin Biochem* 32: 575-583, 1995.
- Sundberg A, Appelkvist E, Backman L, Dallner G. Urinary pi-class glutathione transferase as an indicator of tubular damage in the human kidney. *Nephron*. 67: 308-316, 1994.

Researcher's name and Organization:

John E. Snawder, Ph.D. D.A.B.T, Division of Applied Research and Technology, National Institute for Occupational Safety & Health (CDC), 4676 Columbia Parkway, MS-C23, Cincinnati, Ohio 45226, Tel: 513-533-8496, Fax: 513-533-8138, E-mail: JTS5@cdc.gov

Mary Ann Butler, Ph.D., Division of Applied Research and Technology, National Institute for Occupational Safety & Health (CDC), 4676 Columbia Parkway, MS-C23, Cincinnati, Ohio 45226, Tel: 513-533-8403, Fax: 513-533-8138, E-mail: MFB6@cdc.gov

John C. Clark, BS., Division of Applied Research and Technology, National Institute for Occupational Safety & Health (CDC), 4676 Columbia Parkway, MS-C23, Cincinnati, Ohio 45226, Tel: 513-533-8198, Fax: 513-533-8138, E-mail: JCC2@cdc.gov

Edwin A Knecht, M.S., Division of Applied Research and Technology, National Institute for Occupational Safety & Health (CDC), 4676 Columbia Parkway, MS-C23, Cincinnati, Ohio 45226, Tel: 513-533-8197, Fax: 513-533-8138, E-mail: EAK1@cdc.gov

Edward F Krieg, Jr, Ph.D., Division of Applied Research and Technology, National Institute for Occupational Safety & Health (CDC), 4676 Columbia Parkway, MS-C22, Cincinnati, Ohio 45226, Tel: 513-533-8160, Fax: 513-533-8510, E-mail: ERK3@cdc.gov

Table 1. Effect of JP8 Exposure Category on Hepatic Alpha Glutathione Transferase (Hep Alpha GST).

Exposure Category	Hep Alpha GST (µg/L)	Hep-Alpha GST Normal Range (µg/L)	Hep-Alpha GST Pre-Post Difference (µg/L)
1 Pre	2.82 ± 2.46	0-11	-----
2 Pre	3.01 ± 2.32	0-11	-----
3 Pre	2.73 ± 2.34	0-11	-----
1 Post	2.81 ± 4.94	0-11	-0.01
2 Post	2.96 ± 2.08	0-11	-0.05
3 Post	2.67 ± 2.50	0-11	-0.06

Table 2. Effect of JP8 Exposure Category on Kidney Proximal Tubule Glutathione Transferase (Neph Alpha GST) and Kidney Distal Tubule Glutathione Transferase (Neph Pi GST).

Exposure Category	Neph-Alpha GST (µg/mg creatinine)	Neph-Alpha GST Normal Range (µg/mg creatinine)	Neph-Alpha GST Pre-Post Difference (µg/mg creatinine)	Neph-Pi GST (µg/mg creatinine)	Neph-Pi GST Normal Range (µg/mg creatinine)	Neph-Pi GST Pre-Post Difference (µg/mg creatinine)
1 Pre	2.13 ± 5.03	0-10	-----	4.71 ± 5.61	0-12	-----
2 Pre	1.43 ± 2.86	0-10	-----	5.00 ± 5.12	0-12	-----
3 Pre	1.02 ± 2.39	0-10	-----	4.32 ± 4.95	0-12	-----
1 Post	2.44 ± 5.74	0-10	0.31	5.71 ± 7.65	0-12	+1.0
2 Post	1.46 ± 2.67	0-10	0.03	5.07 ± 8.05	0-12	+0.07
3 Post	0.71 ± 2.83	0-10	-0.29	2.93 ± 3.20	0-12	-1.39

Table 3. Effect of JP8 Exposure Category on Urine Creatinine Levels.

Exposure Category	Urine Creatine (mg/ml)	Urine Creatinine Normal Range (mg/ml)	Urine Creatine Pre-Post Difference (mg/ml)
1 Pre	1.82 ± 1.01	0.25-4.0	-----
2 Pre	1.71 ± 0.96	0.25-4.0	-----
3 Pre	1.96 ± 0.96	0.25-4.0	-----
1 Post	1.62 ± 0.90	0.25-4.0	-0.20
2 Post	1.84 ± 0.97	0.25-4.0	+0.13
3 Post	2.54 ± 1.15	0.25-4.0	+0.58



UNITED STATES AIR FORCE AFIOH

JP-8 Final Risk Assessment

Ronald K. Kendall
Ernest Smith

Texas Tech University
The Institute of Environmental and Human Health
1207 Gilbert Drive
Lubbock, TX 79416

Leslie B. Smith, Major, USAF, BSC
Roger L. Gibson, Lieutenant Colonel, USAF

20060221 082

August 2001

*Approved for public release;
distribution is unlimited.*

Air Force Institute for Operational Health
Risk Analysis Directorate
Environmental Analysis Division
2513 Kennedy Circle
Brooks City-Base TX 78235-5116

NOTICES

This report is published as received and has not been edited by the staff of the Air Force Institute for Operational Health (AFIOH).

Publication of this report does not constitute approval or disapproval of the ideas or findings. It is published in the interest of scientific and technical information (STINFO) exchange.

When Government drawings, specifications, or other data are used for any purpose other than in connection with a definitely Government-related procurement, the United States Government incurs no responsibility or any obligation whatsoever. The fact that the Government may have formulated or in any way supplied the said drawings, specifications, or other data, is not to be regarded by implication, or otherwise in any manner construed, as licensing the holder or any other person or corporation; or as conveying any rights or permission to manufacture, use, or sell any patented invention that may in any way be related thereto.

The mention of trade names or commercial products in this publication is for illustration purposes and does not constitute endorsement or recommendation for use by the United States Air Force.

The Office of Public Affairs has reviewed this report, and it is releasable to the National Technical Information Service, where it will be available to the general public, including foreign nationals.

This report has been reviewed and is approved for publication.

Government agencies and their contractors registered with Defense Technical Information Center (DTIC) should direct requests for copies to: Defense Technical Information Center, 8725 John J. Kingman Rd., STE 0944, Ft. Belvoir, VA 22060-6218.

Non-Government agencies may purchase copies of this report from: National Technical Information Services (NTIS), 5285 Port Royal Road, Springfield, VA 22161-2103.

//signed//

GROVER K. YAMANE, Col, USAF, MC, SFS
Preventive Medicine Consultant

//signed//

CANDACE L. MCCALL, Lt Col, USAF, BSC
Chief, Risk Assessment Division

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.				
1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE August 2001		3. REPORT TYPE AND DATES COVERED Final
4. TITLE AND SUBTITLE JP-8 Final Risk Assessment			5. FUNDING NUMBERS F41624-99-2-0002	
6. AUTHOR(S) *Kendall, Ronald K.; *Smith, Ernest Smith, Leslie B.; Gibson, Roger L.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) * Texas Tech University The Institute of Environmental and Human Health 1207 Gilbert Drive Lubbock , TX 79416			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) Air Force Institute for Operational Health Risk Analysis Directorate Risk Assessment Division 2513 Kennedy Circle Brooks City-Base, TX 78235-5116			10. SPONSORING/MONITORING AGENCY REPORT NUMBER IOH-RS-BR-SR-2005-0003	
11. SUPPLEMENTARY NOTES Prepared in cooperation with The Institute of Environmental and Human Health (TIEHH) for the Air Force Institute for Operational Health (AFIOH).				
12a. DISTRIBUTION AVAILABILITY STATEMENT Approved for public release; distribution is unlimited.			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words) The JP-8 Final Risk Assessment is a collection of several studies assessing the health and performance effects from acute exposure to Jet Propellant type 8 (JP-8) jet fuel. Exposed subjects were active duty Air Force personnel who worked with or were routinely exposed to JP-8 in the performance of their duties. Non-exposed subjects were active duty Air Force personnel who did not have routine contact with JP-8 during the performance of their duties. Assessments included JP-8 exposure in the immediate personal environment, JP-8 body burden, neurologic effects, hormonal effects, immunological effects, liver/renal function, cytotoxic/genotoxic effects, glutathione-S-transferase activity, and self-reported health status.				
14. SUBJECT TERMS JP-8, Jet Fuel, Human Risks, Occupational Health			15. NUMBER OF PAGES 186	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT UL	